AI-designed miniproteins unlock control of GPCR signaling Study demonstrates that computationally-designed miniproteins can modulate GPCR activity in native cellular environments, expanding access to a major drug target family. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/ai-designed-miniproteins-unlock-control-of-gpcr-signaling-17208?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8o7WUg7Idl3S1RjjWIyU6fsc1jkRuUpVuhQ043ikSWj46QYVUidvfFc5NTsICqQjyqvnqW11IdDLZUaaPFBpAcoUf0BQ&_hsmi=422305080&utm_content=422305080&utm_source=hs_email G-protein-coupled receptors (GPCRs) are the largest and most versatile of cell surface receptors, with a broad repertoire of ligands and functions. Around one-third of approved medicines act on these membrane proteins, targeting a wide range of diseases from allergic rhinitis to pain, hypertension, and schizophrenia.